CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

Company Overview

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Key Stats

• Today's Range: $2.04 to $2.09
• 50-Day Range: $2.01 to $2.74
• 52-Week Range: $1.20 to $4.05
• Volume: 5,887 shs
• Average Volume: 78,089 shs
• Market Capitalization: $22.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

CytoMed Therapeutics Stock Analysis - MarketRank™

CytoMed Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 545th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CytoMed Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CytoMed Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

CytoMed Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of CytoMed Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoMed Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoMed Therapeutics does not currently pay a dividend.

Dividend Growth

CytoMed Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.24% of the float of CytoMed Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytoMed Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoMed Therapeutics has recently decreased by 11.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

CytoMed Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CytoMed Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.04% of the stock of CytoMed Therapeutics is held by institutions.

GDTC Stock Analysis - Frequently Asked Questions

How have GDTC shares performed this year?

CytoMed Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, GDTC shares have decreased by 38.5% and is now trading at $2.09.
View the best growth stocks for 2025 here.

When did CytoMed Therapeutics IPO?

CytoMed Therapeutics (GDTC) raised $10 million in an IPO on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share.

How do I buy shares of CytoMed Therapeutics?

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CytoMed Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Today: 6/16/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GDTC
• CIK: 1873093
• Web: w2.cytomed.sg
• Phone: 65-6250-7738
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +139.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 21.54
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $69.50 thousand
• Price / Sales: 328.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 2.68

Miscellaneous

• Outstanding Shares: 10,940,000
• Free Float: N/A
• Market Cap: $22.86 million
• Optionable: Not Optionable
• Beta: -0.33